Cargando…

Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial

OBJECTIVE: The aim of this study was to find the optimum dosage of dexmedetomidine in Spinal Orthopedic Scoliosis Correction Surgery when used in combination with propofol and remifentanil in American Society of Anesthesiologists (ASA) III patients with severe scoliosis undergoing intraoperative wak...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting, Mudabbar, Muhammad Saqib, Chen, Tao, Jia, Hong, Fu, Qiang, Liu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913085/
https://www.ncbi.nlm.nih.gov/pubmed/35451391
http://dx.doi.org/10.1097/MD.0000000000028993
_version_ 1784667338142908416
author Yang, Ting
Mudabbar, Muhammad Saqib
Chen, Tao
Jia, Hong
Fu, Qiang
Liu, Bin
author_facet Yang, Ting
Mudabbar, Muhammad Saqib
Chen, Tao
Jia, Hong
Fu, Qiang
Liu, Bin
author_sort Yang, Ting
collection PubMed
description OBJECTIVE: The aim of this study was to find the optimum dosage of dexmedetomidine in Spinal Orthopedic Scoliosis Correction Surgery when used in combination with propofol and remifentanil in American Society of Anesthesiologists (ASA) III patients with severe scoliosis undergoing intraoperative wake-up test. MATERIALS AND METHODS: We selected a total of 60 ASA III ≤40 years old patients who underwent Spinal Orthopedic Scoliosis Correction Surgery (SOSCS) and randomized them into groups A, B, and C. Group A was administered 0.2 μg/(kg·h) of dexmedetomidine, group B 0.3 μg/(kg·h), and group C 0.4 μg/(kg·h). The main parameters monitored were: wake-up time; wake-up quality; adverse effects that occur while the patient is awake; postoperative awareness of intraoperative wake-up test; heart rate (HR); mean arterial pressure (MAP); and oxygen saturation (SpO(2)). Values of these parameters were monitored at 7 timestamps separated by 5 minutes >30 minutes. RESULTS: Group B had a higher MAP at 10 minutes before wake-up (P = .03) and at the moment of wake-up (P = .04) than group A. The Wake-up time of group A was 14.95 ± 7.42 minutes, group B was 14.7 ± 6.52 minutes, which was significantly shorter than that of group C 21.3 ± 10.02 minutes (P = .02). The wake-up quality was excellent. All other parameters had no significant statistical differences. CONCLUSION: Doses of 0.2 to 0.3 μg/(kg·h) have shorter wake-up time and fewer hemodynamic fluctuations compared to 0.4 μg/(kg·h).
format Online
Article
Text
id pubmed-8913085
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89130852022-03-15 Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial Yang, Ting Mudabbar, Muhammad Saqib Chen, Tao Jia, Hong Fu, Qiang Liu, Bin Medicine (Baltimore) 3300 OBJECTIVE: The aim of this study was to find the optimum dosage of dexmedetomidine in Spinal Orthopedic Scoliosis Correction Surgery when used in combination with propofol and remifentanil in American Society of Anesthesiologists (ASA) III patients with severe scoliosis undergoing intraoperative wake-up test. MATERIALS AND METHODS: We selected a total of 60 ASA III ≤40 years old patients who underwent Spinal Orthopedic Scoliosis Correction Surgery (SOSCS) and randomized them into groups A, B, and C. Group A was administered 0.2 μg/(kg·h) of dexmedetomidine, group B 0.3 μg/(kg·h), and group C 0.4 μg/(kg·h). The main parameters monitored were: wake-up time; wake-up quality; adverse effects that occur while the patient is awake; postoperative awareness of intraoperative wake-up test; heart rate (HR); mean arterial pressure (MAP); and oxygen saturation (SpO(2)). Values of these parameters were monitored at 7 timestamps separated by 5 minutes >30 minutes. RESULTS: Group B had a higher MAP at 10 minutes before wake-up (P = .03) and at the moment of wake-up (P = .04) than group A. The Wake-up time of group A was 14.95 ± 7.42 minutes, group B was 14.7 ± 6.52 minutes, which was significantly shorter than that of group C 21.3 ± 10.02 minutes (P = .02). The wake-up quality was excellent. All other parameters had no significant statistical differences. CONCLUSION: Doses of 0.2 to 0.3 μg/(kg·h) have shorter wake-up time and fewer hemodynamic fluctuations compared to 0.4 μg/(kg·h). Lippincott Williams & Wilkins 2022-03-11 /pmc/articles/PMC8913085/ /pubmed/35451391 http://dx.doi.org/10.1097/MD.0000000000028993 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 3300
Yang, Ting
Mudabbar, Muhammad Saqib
Chen, Tao
Jia, Hong
Fu, Qiang
Liu, Bin
Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
title Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
title_full Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
title_fullStr Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
title_full_unstemmed Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
title_short Dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: A randomized controlled trial
title_sort dexmedetomidine dosage in critically ill patients undergoing intraoperative wake-up test: a randomized controlled trial
topic 3300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913085/
https://www.ncbi.nlm.nih.gov/pubmed/35451391
http://dx.doi.org/10.1097/MD.0000000000028993
work_keys_str_mv AT yangting dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial
AT mudabbarmuhammadsaqib dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial
AT chentao dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial
AT jiahong dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial
AT fuqiang dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial
AT liubin dexmedetomidinedosageincriticallyillpatientsundergoingintraoperativewakeuptestarandomizedcontrolledtrial